'Triple G' Agonist Hits New Weight-Loss Heights

An editorial on phase 2 results from treating people with obesity or overweight but not diabetes with retatrutide, a triple hormone–receptor agonist, calls the weight loss achieved "unprecedented."

Related Keywords

San Diego ,California ,United States ,New Haven ,Connecticut ,Massachusetts ,Texas ,Dallas ,Yale University ,Boston ,American ,Leem Kaplan ,Aniam Jastreboff ,Victoza Saxenda ,Mary Elizabeth Patti ,Ozempic Wegovy ,Julio Rosenstock ,Yale Obesity Research Center ,Drug Administration ,American Diabetes Association ,Dallas Diabetes Research Center At Medical City ,Nutrition Institute At Massachusetts ,Astrazeneca ,Joslin Diabetes Center ,New England Journal ,Scientific Sessions ,Dallas Diabetes Research Center ,Medical City ,Agonist Has Added Effect ,Liver Fat Clearance ,Nutrition Institute ,Massachusetts General Hospital ,Obesity ,Bese ,Weight Management ,Weight Loss ,Receptors ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Liver ,Body Mass Index Bmi ,Metabolism ,Etabolic ,Osteoarthritis Oa ,Steoarthritis Generalized ,A Osteoarthritis ,Egenerative Joint Disease Djd ,Rthritis Degenerative ,Eneralized Osteoarthritis ,Degenerative Arthritis ,Sleep Apnea ,Sleep Di ,